Table 4.

Analysis of Polymorphism and Clinical Features in Glioma Patient Progression-free Survival

Characteristic	Patients (n)	Events (n)	Rate (%)	Univariate Analysis		Multivariable Analysis
				HR (95% CI)	p Value	HR (95% CI)	p Value
Age
<40 years	267	239	89.51	ref	ref	ref	ref
≥40 years	338	324	95.86	1.19 (1.00–1.40)	0.047*	1.22 (1.03–1.45)	0.0191*
WHO Grade
I–II	382	353	92.41	ref	ref
III–IV	223	210	94.17	1.15 (0.97–1.36)	0.116
Surgery
STR and NTR	189	183	96.83	ref	ref	ref	ref
GTR	416	380	91.35	0.58 (0.48–0.69)	<0.001*	0.61 (0.51–0.74)	<0.001*
Chemotherapy
No	335	351	104.78	ref	ref	ref	ref
Platinum	124	116	93.55	0.99 (0.80–1.22)	0.916	0.97 (0.80–1.20)	0.759
Temozolomide	52	32	61.54	0.35 (0.24–0.50)	<0.001*	0.37 (0.26–0.54)	<0.001*
Nimustine	74	64	86.49	0.73 (0.56–0.96)	0.022*	0.88 (0.67–1.16)	0.377
rs11337
GG	384	355	92.45	ref	ref	ref	ref
GT	194	187	96.39	1.21 (1.01–1.44)	0.0367*	1.19 (0.99–1.43)	0.0519
TT	27	21	77.78	0.75 (0.49–1.17)	0.209	0.88 (0.67–1.16)	0.113
Sex
Male	335	310	92.54	ref	ref
Female	270	253	93.70	1.10 (0.93–1.30)	0.263
Radiotherapy
No	60	55	91.67	ref	ref
Conformal radiotherapy	162	137	84.57	1.13 (0.83–1.56)	0.436
Gamma knife	383	371	96.87	1.21 (0.91–1.60)	0.199
rs1044129
GG	105	102	97.14	ref	ref
GA	312	290	92.95	0.92 (0.73–1.15)	0.453
AA	183	171	93.44	0.95 (0.75–1.22)	0.698
rs1053667
TT	465	423	90.97	ref	ref
TC	135	126	93.33	0.95 (0.78–1.16)	0.604
CC	5	4	80.00	0.66 (0.25–1.77)	0.411
rs1059394
CC	80	76	95.00
CT	225	233	103.56	0.89 (0.69–1.15)	0.368
TT	270	254	94.07	0.96 (0.74–1.24)	0.762
rs2847153
GG	223	211	94.62
GA	295	272	92.20	0.91 (0.76–1.09)	0.299
AA	86	79	91.86	0.91 (0.70–1.17)	0.456

STR, subtotal resection; NTR, near-total resection; GTR, gross total resection; ref, reference compared with other indicators. *p ≤ 0.05 indicates statistical significance.